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 Treatment of the common life-shortening inherited disease cystic fibrosis (CF) is 
witnessing a revolution.  Up until 2012, therapies were directed exclusively against disease 
symptoms.  These included time-consuming chest physiotherapy and small mountain of drugs 
to clear mucus obstructed air passageways, fight lung infections, dampen inflammatory 
responses and replace missing pancreatic enzymes.  Together with specialised patient care in 
CF centres, improvements in symptomatic therapy increased average life expectancy from 
~10 years in the 1960s to ~40 years in 2010 in North America and Western Europe. 
 
 In 2012, ivacaftor (KalydecoTM; VX-770; Vertex Pharmaceuticals), the first drug 
therapy to target the root cause of CF, mutant cystic fibrosis transmembrane conductance 
regulator (CFTR) was approved by the US Food and Drug Administration (FDA) and the 
European Medicines Agency (EMA) for patients carrying the mutation G551D-CFTR.  The 
clinical impact of ivacaftor was simply astonishing: forced expiratory volume in one second 
(FEV1), a blunt measure of lung function, increased by 10% after just 2 weeks in adult 
patients many with irreversibly damaged lungs; the frequency of hospitalisation for treatment 
of lung infections, a measure of disease stability, improved by 55%; individuals treated with 
the drug gained weight (>2.5 kg over 48 weeks) and sweat chloride levels decreased by 
almost 50 mmol/l, improvements unheard of in previous clinical trials of new therapies for 
CF.  Use of ivacaftor was soon extended to nine other CF mutations, representing ~6% of all 
individuals living with CF worldwide.  This year, use of ivacaftor has been extended to a 
further 28 mutations, bringing the total to 38 (https://www.cff.org/News/News-
Archive/2017/FDA-Approves-Ivacaftor-for-Five-Splice-Mutations/).  For two reasons, the 
latest extension of ivacaftor’s use is highly significant.  First, five of the mutations listed 
cause splicing defects, which reduce the amount of CFTR protein delivered to the plasma 
membrane.  Second, laboratory data played a pivotal role in expanding the use of ivacaftor to 
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some rare CF mutations.  The willingness of the FDA to consider laboratory data is to be 
applauded.  It raises the exciting possibility that laboratory data might be further employed to 
expand the clinical utility of ivacaftor and other innovative new therapies for CF. 
 
 The development of ivacaftor is notable for several reasons.  First, it benefitted 
enormously from a wealth of basic science research, which identified the CFTR gene, 
demonstrated its function as an ATP-gated epithelial Cl- channel and elucidated how CF-
causing mutations disrupt CFTR expression and function.  Second, it was assisted by high 
quality patient registry data and clinical trial networks.  Third, the willingness of the CF 
community to provide help and advice to the Vertex Pharmaceutical team. Finally, the unique 
collaboration between the US CF Foundation and Vertex Pharmaceuticals, which led to a 
new model for drug development termed venture philanthropy. 
 
 When compared with G551D-CFTR and other mutations that affect only CFTR 
gating (the pattern of channel opening and closing), transformational therapy for F508del-
CFTR, the most common CF mutation is an altogether more challenging proposition because 
the mutation has multiple impacts upon CFTR.  F508del-CFTR is a temperature-sensitive 
folding mutation.  At normal body temperature, the misfolded mutant protein is 
predominantly retained in the endoplasmic reticulum and degraded by the proteasome.  Little 
if any F508del-CFTR protein traffics to its correct cellular location, the apical membrane of 
epithelia.  The small fraction that does make it forms highly unstable Cl- channels with a 
pronounced defect in channel gating.  Thus, small molecules with two types of activity are 
required to restore function to F508del-CFTR: first, correctors, so called because they 
overcome the processing defect of F508del-CFTR and deliver the mutant protein to the apical 
membrane.  Second, potentiators to enhance channel gating following CFTR phosphorylation 
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by protein kinase A.  Combination therapy with lumacaftor (VX-809; Vertex 
Pharmaceuticals), the first corrector tested in the clinic, and ivacaftor (Orkambi) increased 
FEV1 by ~3%, but disease stability by 30-40%, leading in 2015 to regulatory approval for 
Orkambi use with CF patients homozygous for the F508del-CFTR mutation. 
 
 This year’s respiratory section of the Journal provides a state-of-the-art overview of 
research to develop transformational therapies for all individual’s living with CF.  It discusses 
lessons from clinical trials of ivacaftor and lumacaftor, their mechanism of action and 
therapeutic strategies under investigation, including mutation-specific schemes to target 
specific types of CF mutations and mutation-independent stratagems applicable to all CF 
mutations.  The section concludes with discussion of the potential utility of new therapies for 
CF in the treatment of chronic obstructive pulmonary disease (COPD) and other respiratory 
diseases. 
 
 De Boeck and Davies introduce the busy pipeline of therapies being tested in the 
clinic and highlight the latest clinical trial data to be announced by press release, triple 
combination therapy with two correctors and a potentiator, which has caused great 
excitement within the CF community.  De Boeck and Davies draw attention to the ethical 
dilemma of withdrawing ivacaftor to test new potentiators and the need for better tests than 
FEV1 to evaluate lung function, particularly in very young children.  They emphasize 
important lessons from the clinical trials of new therapies conducted to date, including the 
evaluation of treatment benefit over the long, not short, term, the design of clinical trials to 
detect unexpected health benefits and the issue of equitable access to transformational 
therapies for all eligible individuals. 
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 There then follows three reviews on ivacaftor, lumacaftor and combination therapy 
for F508del-CFTR with correctors and potentiators.  These reviews introduce the molecular 
defects in CFTR targeted by potentiators and correctors, discuss their mechanism of action 
and highlight the wide spectrum of CF mutations that might benefit from these small 
molecules. 
 
 Jih, Lin, Sohma and Hwang review proof-of-concept studies using ATP analogues 
and early studies of potentiators identified by hypothesis-led studies prior to the 
implementation of high-throughput screening to discover efficacious CFTR modulators.  
Using a sophisticated gating model, the authors explain how ivacaftor potentiates both ATP-
dependent and ATP-independent gating of CFTR (Eckford PD et al. J Biol Chem. 2012; 
287:36639-49; Jih KY, Hwang TC. Proc Natl Acad Sci U S A. 2013; 110:4404-9).  Of note, 
Hwang and his colleagues draw attention to the therapeutic potential of combinations of 
potentiators acting at distinct binding-sites to achieve enhanced rescue of mutant channel 
gating through pharmacological synergy. 
 
 Mijnders, Kleizen and Braakman discuss the challenge of correcting CFTR structure 
with small molecules to repair the defective processing of CF mutants, particularly F508del-
CFTR, which not only causes misfolding of the first nucleotide-binding domain (NBD1), but 
perturbs CFTR domain assembly.  They emphasize that CFTR correctors are likely to have 
wider utility than CF processing mutations because CF mutations that alter Cl- channel 
function cause structural defects and hence, CFTR misfolding.  Braakman and colleagues 
advocate that high-throughput screening is the most practical approach to identify new 
correctors for rare CF mutations unresponsive to lumacaftor. 
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 Hanrahan, Matthes, Carlile and Thomas argue persuasively that evidence for multiple 
corrector binding sites provides a strong rationale for rescue of F508del-CFTR with 
combinations of two or more correctors.  The authors draw attention to the problem of drug-
drug interactions encountered with lumacaftor and ivacaftor, cautioning that combination 
therapy increases the potential for drug-drug interactions with potentially far reaching 
consequences.  However, Hanrahan and colleagues are optimistic that the development of 
second generation correctors and corrector combinations will improve significantly the 
quality of life for most individuals living with CF. 
 
 The next two reviews address transformational therapies for individuals with rare CF 
mutations including missense, nonsense and splicing mutations.  As for the preceding 
reviews, mutation-specific therapies are the focus of most attention.  Oliver, Han, Sorscher 
and Cutting discuss the classification of CF mutations, the molecular complexity of 
individual CF mutations and the challenge of developing precision medicines for all forms of 
CF.  They review the development of ivacaftor, emphasizing the importance of molecular 
understanding for regulatory approval, but caution that expansion of ivacaftor to very rare CF 
mutations will require alternatives to conventional clinical trial design.  Cutting and 
colleagues advocate an integrated approach combining in vitro studies using cell-based model 
systems with in silico predictions and pre-clinical testing to predict the response of CF 
mutations to correctors and potentiators. 
 
 Oren, Pranke, Kerem and Sermet-Gaudelus explain the molecular consequences of 
nonsense and splicing mutations.  They review the development of ataluren, which 
suppresses premature termination codons (PTCs) caused by nonsense mutations without 
affecting termination at normal stop codons, discussing potential causes of variable drug 
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responses, which might have contributed to the drug’s failure in clinical trials.  Because PTC 
suppression might introduce the wrong amino acid, leading to a faulty protein, the authors 
highlight the value of combining PTC suppression with correctors and potentiators.  They 
also draw attention to the therapeutic potential of antisense oligonucleotides (ASOs), 
chemically-modified synthetic RNA-like molecules to correct nonsense and splicing 
mutations.  Of note, ASO-based therapies have recently received regulatory approval for two 
genetic diseases, spinal muscular atrophy and Duchenne muscular dystrophy. 
 
 In the final review addressing mutation-specific therapies, Callebaut, Hoffmann and 
Mornon discuss the role of structural data in CF drug development.  The authors highlight 
new insight into CFTR structure-function relationships from the first high-resolution 
structures of CFTR solved by cryo-electron microscopy (Zhang Z, Chen J. Cell. 2016; 
167:1586-1597.e9; Zhang Z et al. Cell. 2017; 170:483-491.e8).  They explain how the 
interface between the NBDs and membrane-spanning domains (MSDs) of CFTR is both a hot 
spot for CF mutations and a potential binding site for CFTR modulators; other potential drug-
binding sites have been identified at the NBD1:NBD2 interface, the location of the two ATP-
binding sites that control channel gating (Kalid O et al. J Comput Aided Mol Des. 2010; 
24:971-91; Hwang TC, Sheppard DN. J Physiol. 2009; 587:2151-61).  Callebaut and 
colleagues advocate an integrated approach to identify high-affinity CFTR modulators, which 
combines knowledge from high-resolution cryo-electron microscopy maps and detailed 3D 
molecular models with information about the conformational stability and flexibility of the 
CFTR protein required for Cl- channel function. 
 
 The next two reviews address two distinct mutation-independent therapeutic strategies 
both with long histories in CF research.  CFTR bypass therapy utilises other pathways for 
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anion transport to restore transepithelial ion transport to CF epithelia, while gene therapy 
aims to replace or repair the faulty CFTR gene in CF epithelial cells.  Both strategies 
predominantly target CF lung disease, unlike orally-bioavailable small molecules, which 
target all affected tissues. 
 
 Li, Salomon, Sheppard, Mall and Galietta compare and contrast the localisation, 
biophysical properties and regulation of the anion channels TMEM16A and SLC26A9 with 
those of CFTR.  Because activation of TMEM16A is transient, the authors explain that long-
acting small molecules that directly target TMEM16A are required for bypass therapy.  By 
contrast, the constitutive activity of SLC26A9 makes it a promising target for CFTR bypass 
therapy.  However, co-expression of SLC26A9 with CFTR argues that SLC26A9 potentiators 
have greatest utility with CF mutants present at the plasma membrane.  The authors also 
introduce an alternative approach to CFTR bypass therapy, self-assembled anion channels 
and artificial anion transporters developed by supramolecular chemists.  They highlight 
proof-of-concept studies which explore the feasibility of bypassing CFTR dysfunction with 
artificial anion channels and transporters and consider the challenges that must be overcome 
to develop these agents as therapeutics for CF. 
 
 Hart and Harrison review gene therapy for CF lung disease, a field that has been 
rejuvenated by rapid advances in gene editing technologies.  The authors describe efforts to 
improve viral vectors, highlighting the important role that new animal models and human 
intestinal organoids have played in vector testing.  They show how DNA nanoparticles have 
improved the delivery of non-viral gene therapy formulations to mouse lungs in vivo, while 
minicircle DNA vectors have achieved higher levels of gene expression and reduced 
inflammatory responses.  Hart and Harrison explain how different gene editing strategies 
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have been used to achieve gene therapy for CF.  They highlight how a “super-exon” has the 
potential to correct many different CF mutations, eliminating the requirement for mutation-
specific gene editing.  The authors are optimistic about the prospects of treating CF with gene 
therapy. 
 
 Solomon, Fu, Rowe and Collawn explain how cigarette smoke, a leading cause of 
COPD results in acquired CFTR dysfunction, characterised by decreased CFTR mRNA, 
reduced protein stability at the plasma membrane and inhibition of channel gating.  They 
review evidence for acquired CFTR dysfunction in other respiratory diseases, including 
asthma and non-CF bronchiectasis, concluding that sub-sets of patients in both diseases 
demonstrate acquired CFTR dysfunction.  Of special note, the authors demonstrate that 
ivacaftor rescues CFTR function after exposure to cigarette smoke and report pilot clinical 
data showing that ivacaftor improves respiratory symptoms in individuals with COPD.  
Given the current lack of effective therapies for COPD, these data suggest that ivacaftor and 
other CFTR modulators have significant therapeutic potential for COPD. 
 
 Although the ten reviews provide an excellent overview of work to develop 
transformational new therapies, some topics have not received the attention they deserve.  
First, studies of correctors have focused only on pharmacological chaperones that interact 
directly with misfolded CFTR.  An alternative approach is proteostasis regulators, which 
target one or more of the many CFTR-interacting proteins that orchestrate and control the 
biosynthesis of CFTR, its delivery to, and expression at the apical membrane (for review, see 
Balch WE et al. Science. 2008; 319:916-9; Amaral MD, Farinha CM. Curr Pharm Des. 2013; 
19:3497-508).  Second, a small number of small molecules have been identified with both 
corrector and potentiator activity, termed corrector-potentiators or dual-acting small 
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molecules (Pedemonte N et al. J Biol Chem. 2011; 286:15215-26; Phuan PW et al. Mol 
Pharmacol. 2011; 80:683-93).  This interesting class of small molecules deserves further 
investigation, but it is currently unclear whether therapeutically-active dual-acting small 
molecules will be developed.  Finally, advances in stem cell research, with the potential to 
generate patient-specific epithelial tissues from induced pluripotent stem cells (iPSCs) 
presents future opportunities for therapy development.  Robust protocols for tissue-specific 
differentiation of patient-derived iPSCs are advancing to the stage where it will soon be 
feasible to profile a panel of existing and emerging CFTR modulators simultaneously for all 
affected tissues in an individual to enable precision medicine (Ahmadi S et al. NPJ Genom 
Med. 2017; 2:12).  The exciting, longer term goal of tissue or organ replacement with patient-
specific cells in which the CFTR mutation is corrected, is being actively pursued by multiple 
laboratories. 
 
 We thank all authors for their excellent contributions, the Journal’s editorial staff for 
their great assistance, CF charities and foundations for supporting our research, our 
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